March 2022 | Targeted Therapies in Oncology

New Methods May Make CAR Therapies More Effective for Patients With CLL

March 30, 2022

Clinical Articles

Research results suggest that CAR T-cell therapy can overcome T cell defects caused by chronic lymphocytic leukemia, with remissions possibly lasting more than a decade for patients with significant disease burden when treated with CD4+ CAR T cells

Exploring Adjuvant Therapies in Renal Cell Carcinoma

March 25, 2022

Clinical Articles

Although numerous therapeutics are available for the management of metastatic renal cell carcinoma in the first-line setting, there are few options and little guidance on the approach to adjuvant therapy.

CARCIK-CD19 Protocol Provides Lymphodepleted Patients Access to CAR T-cell Treatment in B-ALL

March 24, 2022

Clinical Articles

Chimeric antigen receptor T cells manufactured using the Sleeping Beauty transposon in donor-derived cells and differentiated toward the cytokine-induced killer cell protocol induce a sustained response with minimal toxicities in patients with B-cell acute lymphoblastic leukemia.

Second-Line Regorafenib/Nivolumab Is Deemed Safe for HCC

March 23, 2022

Clinical Articles

For patients with hepatocellular carcinoma treated in the second-line setting, the combination of regorafenib and nivolumab following 2 cycles of regorafenib monotherapy appeared safe, according to phase 1/2a study.

Viral Etiology, NLR Lead to Better Responses With Atezolizumab/Bevacizumab Combo in HCC

March 23, 2022

Clinical Articles

Treatment with atezolizumab plus bevacizumab in the first-line setting achieved better responses for patients with unrespectable hepatocellular carcinoma when their disease had a viral versus nonviral etiology and neutrophil-to-lymphocyte ratio was less than 3.6.

Targeted Therapy Is Considered a Necessity for Metastatic GIST

March 23, 2022

Clinical Articles

Targeted therapy with tyrosine kinase inhibitors is necessary after surgery for patients with metastatic gastrointestinal stromal tumors with residual disease requiring resection to prevent disease recurrence.

Promising ICIS Are Explored in Sarcoma, But Disparate Histologies Are Challenging

March 22, 2022

Clinical Articles

Patients with sarcoma may respond to treatment with immune checkpoint inhibitors, but identifying patients who are most likely to respond to this therapy is an ongoing obstacle and suggests the need for further research.

ARI-0001 CAR T-Cell Treatment Shows Promise in R/R CLL, Small Study Shows

March 21, 2022

Clinical Articles

Successful CAR T-cell production was achieved in all 11 patients who underwent apheresis and cell production but were still alive at the time of infusion, according to result presented during the BMT- EHA 4th European CAR T-Cell Meeting.

Barriers to Access for COVID-19 Treatments Put Patients With Cancer at Risk

March 19, 2022

Clinical Articles

Amid the surge of the omicron variant, the FDA issued an emergency use authorization for the orally administered antiviral combination, which can reduce the rate hospitalization or death by 87% compared with no treatment.